Basic science| Volume 57, ISSUE 5, P993-998, May 2001

Increased intracellular doxorubicin by anti-Fas monoclonal antibody: a mechanism that enhances the cytotoxicity in renal cell carcinoma cells


      Objectives. To investigate the effect of anti-Fas monoclonal antibody (mAb) on the intracellular concentration of doxorubicin in renal cell carcinoma (RCC) cells. Little is known about the influence of anti-Fas mAb on the intracellular concentration of chemotherapeutic agents.
      Methods. The concentration of intracellular doxorubicin was determined by high-performance liquid chromatography. The mRNA and protein levels of multidrug resistance-associated protein gene were evaluated by reverse transcriptase-polymerase chain reaction and immunocytochemistry, respectively.
      Results. An increased concentration of doxorubicin inside the cells was found: 2.4-fold in ACHN cells (a human RCC cell line) after treatment with doxorubicin combined with anti-Fas mAb compared with doxorubicin alone. Of the five cases of freshly derived RCC cells treated with doxorubicin and anti-Fas mAb, the intracellular concentration of doxorubicin was increased 2.3 and 2.7-fold in two of them, respectively. Furthermore, both the mRNA and the protein levels of the multidrug resistance-associated protein gene were downregulated after treatment of ACHN cells with anti-Fas mAb. Treatment of ACHN cells with a combination of anti-Fas mAb and doxorubicin resulted in a potentiation of the doxorubicin-mediated cytotoxicity.
      Conclusions. The increased intracellular concentration of doxorubicin by anti-Fas mAb might be one of the mechanisms responsible for the enhancement of doxorubicin-mediated cytotoxicity in RCC cells.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kartner N
        • Riordan J.R
        • Ling V
        Cell surface P glycoprotein associated with multidrug resistance in mammalian cell lines.
        Science. 1983; 221: 1285-1288
        • Cole S.P.C
        • Bhardwaj G
        • Gerlach J.H
        • et al.
        Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.
        Science. 1992; 258: 1650-1654
        • Slapak C.A
        • Mizunuma N
        • Kufe D.W
        Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells.
        Blood. 1994; 84: 3113-3121
        • Yu D.S
        • Chang S.Y
        • Ma C.P
        The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines.
        Br J Urol. 1998; 82: 544-547
        • Nooter K
        • Herweijer H
        Multidrug resistance (MDR) genes in human cancer.
        Br J Cancer. 1991; 63: 663-669
        • Breuninger L.M
        • Paul S
        • Gaughan K
        • et al.
        Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution.
        Cancer Res. 1995; 55: 5342-5347
        • Oehm A
        • Behrmann I
        • Falk W
        • et al.
        Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily.
        J Biol Chem. 1992; 267: 10709-10715
        • Suda T
        • Takahashi T
        • Golstein P
        • et al.
        Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.
        Cell. 1993; 75: 1169-1178
        • Ogasawara J
        • Watanabe-Fukunaga R
        • Adachi M
        • et al.
        Lethal effect of the anti-Fas antibody in mice.
        Nature. 1993; 364: 806-809
        • Itoh N
        • Yonehara S
        • Ishii A
        • et al.
        The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.
        Cell. 1991; 66: 233-243
        • Wu X.X
        • Mizutani Y
        • Kakehi Y
        • et al.
        Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by Adriamycin.
        Cancer Res. 2000; 60: 2912-2918
      1. Hay R, Macy M, Chen TR, et al: Cell Lines and Hybridomas, 6th ed. New York, American Type Culture Collection, 1988, pp 156–211.

        • Mizutani Y
        • Bonavida B
        • Fukumoto M
        • et al.
        Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.
        J Immunother. 1995; 17: 78-87
        • Wu X.X
        • Mizutani Y
        • Kakehi Y
        • et al.
        Expression of major histocompatibility complex antigens and adhesion molecules on renal cell carcinoma cells, and effect of interferon-α and/or cimetidine on the expression.
        Acta Urol Jpn. 1998; 44: 621-626
        • Shinozawa S
        • Mimaki Y
        • Araki Y
        • et al.
        Determination of the concentration of Adriamycin and its metabolites in the serum and tissues of Ehrlich carcinoma-bearing mice by high-performance liquid chromatography.
        J Chromatogr. 1980; 196: 463-469
        • Kim W.J
        • Kakehi Y
        • Kinoshita H
        • et al.
        Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-s-transferase-π (GST-π) and DNA topoisomerase II (TOPOII) genes in renal cell carcinomas and normal kidney.
        J Urol. 1996; 156: 506-511
        • Volm M
        • Kastel M
        • Mattern J
        • et al.
        Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
        Cancer. 1993; 71: 3981-3987
        • Kubo H
        • Sumizawa T
        • Koga K
        • et al.
        Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas.
        Int J Cancer. 1996; 69: 488-494
        • Mizutani Y
        • Yoshida O
        Overcoming tumor necrosis factor-α resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-α.
        Cancer. 1994; 73: 730-737
        • Mizutani Y
        • Wu X.X
        • Yoshida O
        • et al.
        Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil.
        Oncol Res. 1999; 6: 979-982
        • Nagata S
        Apoptosis by death factor.
        Cell. 1997; 88: 355-365
        • Yu D.S
        • Sun G.H
        • Ma C.P
        • et al.
        Cocktail modulator mixtures for overcoming multidrug resistance in renal cell carcinoma.
        Urology. 1999; 54: 377-381
        • Naito S
        • Koike K
        • Ono M
        • et al.
        Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance.
        Oncol Res. 1998; 10: 123-132
        • Jonsson O
        • Behnam-Motlagh P
        • Persson M
        • et al.
        Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
        Biochem Pharmacol. 1999; 58: 1801-1806
        • Grant C.E
        • Valdimarsson G
        • Hipfner D.R
        • et al.
        Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs.
        Cancer Res. 1994; 54: 357-361
        • Berger W
        • Elbling L
        • Hauptmann E
        • et al.
        Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells.
        Int J Cancer. 1997; 73: 84-93
        • Cole S.P
        • Sparks K.E
        • Fraser K
        • et al.
        Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
        Cancer Res. 1994; 54: 5902-5910
        • Beinert T
        • Munzing S
        • Possinger K
        • et al.
        Increased expression of the tetraspanins CD53 and CD63 on apoptotic human neutrophils.
        J Leukoc Biol. 2000; 67: 369-373